Dr. Peter M. Gordon
Claim this profileUniversity of Minnesota/Masonic Cancer Center
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
13 reported clinical trials
39 drugs studied
Area of expertise
1Leukemia
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
2Lymphoblastic Leukemia-Lymphoma
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
Affiliated Hospitals
Clinical Trials Peter M. Gordon is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Leukemia and Lymphoma
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Recruiting1 award Phase 210 criteria
More about Peter M. Gordon
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Peter M. Gordon has experience with
- Cyclophosphamide
- Vincristine Sulfate
- Dexamethasone
- Etoposide
- Pegaspargase
- Prednisolone
Breakdown of trials Peter M. Gordon has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter M. Gordon specialize in?
Peter M. Gordon focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 fusion positive.
Is Peter M. Gordon currently recruiting for clinical trials?
Yes, Peter M. Gordon is currently recruiting for 5 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Peter M. Gordon has studied deeply?
Yes, Peter M. Gordon has studied treatments such as Cyclophosphamide, Vincristine Sulfate, Dexamethasone.
What is the best way to schedule an appointment with Peter M. Gordon?
Apply for one of the trials that Peter M. Gordon is conducting.
What is the office address of Peter M. Gordon?
The office of Peter M. Gordon is located at: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota 55455 United States. This is the address for their practice at the University of Minnesota/Masonic Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.